Recursion Pharmaceuticals, Inc. (RXRX)
RXRX Stock Price Chart
Explore Recursion Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze RXRX price movements and trends.
RXRX Company Profile
Discover essential business fundamentals and corporate details for Recursion Pharmaceuticals, Inc. (RXRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Apr 2021
Employees
800.00
Website
https://www.recursion.comCEO
Najat Khan
Description
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Financial Timeline
Browse a chronological timeline of Recursion Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.25, while revenue estimate is $10.97m.
Earnings released on 6 May 2026
EPS came in at -$0.22 surpassing the estimated -$0.30 by +26.67%, while revenue for the quarter reached $6.30m , missing expectations by -60.06%.
Earnings released on 25 Feb 2026
EPS came in at -$0.21 surpassing the estimated -$0.28 by +25.00%, while revenue for the quarter reached $35.35m , beating expectations by +44.04%.
Earnings released on 5 Nov 2025
EPS came in at -$0.36 surpassing the estimated -$0.38 by +5.26%, while revenue for the quarter reached $5.18m , missing expectations by -78.93%.
Earnings released on 5 Aug 2025
EPS came in at -$0.41 falling short of the estimated -$0.35 by -17.14%, while revenue for the quarter reached $19.10m , missing expectations by -4.13%.
Earnings released on 5 May 2025
EPS came in at -$0.50 falling short of the estimated -$0.44 by -13.64%, while revenue for the quarter reached $14.75m , beating expectations by +5.62%.
Earnings released on 28 Feb 2025
EPS came in at -$0.53 falling short of the estimated -$0.44 by -20.45%, while revenue for the quarter reached $4.51m , missing expectations by -76.31%.
Earnings released on 6 Nov 2024
EPS came in at -$0.34 falling short of the estimated -$0.33 by -3.03%, while revenue for the quarter reached $26.08m , beating expectations by +43.53%.
Earnings released on 8 Aug 2024
EPS came in at -$0.40 falling short of the estimated -$0.35 by -14.29%, while revenue for the quarter reached $14.42m , beating expectations by +8.73%.
Earnings released on 9 May 2024
EPS came in at -$0.39 surpassing the estimated -$0.43 by +9.30%, while revenue for the quarter reached $13.79m , beating expectations by +9.04%.
Earnings released on 27 Feb 2024
EPS came in at -$0.40 surpassing the estimated -$0.46 by +13.04%, while revenue for the quarter reached $10.89m , missing expectations by -46.48%.
Earnings released on 9 Nov 2023
EPS came in at -$0.43 falling short of the estimated -$0.38 by -13.16%, while revenue for the quarter reached $10.10m , missing expectations by -50.79%.
Earnings released on 8 Aug 2023
EPS came in at -$0.38 matching the estimated -$0.38, while revenue for the quarter reached $11.02m , missing expectations by -7.51%.
Earnings released on 8 May 2023
EPS came in at -$0.34 matching the estimated -$0.34, while revenue for the quarter reached $12.13m , missing expectations by -15.97%.
Earnings released on 27 Feb 2023
EPS came in at -$0.31 falling short of the estimated -$0.15 by -106.67%, while revenue for the quarter reached $13.68m , missing expectations by -42.54%.
Earnings released on 8 Nov 2022
EPS came in at -$0.35 surpassing the estimated -$0.36 by +2.78%, while revenue for the quarter reached $13.05m , beating expectations by +90.74%.
Earnings released on 9 Aug 2022
EPS came in at -$0.38 falling short of the estimated -$0.35 by -8.57%, while revenue for the quarter reached $7.65m , beating expectations by +43.49%.
Earnings released on 10 May 2022
EPS came in at -$0.33 falling short of the estimated $0.51 by -164.71%, while revenue for the quarter reached $5.30m , missing expectations by -93.69%.
Earnings released on 23 Mar 2022
EPS came in at -$0.38 falling short of the estimated -$0.30 by -26.67%, while revenue for the quarter reached $2.50m , missing expectations by -58.56%.
Earnings released on 10 Nov 2021
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $2.50m , missing expectations by -1.34%.
Earnings released on 13 Aug 2021
EPS came in at -$0.31 falling short of the estimated -$0.23 by -34.78%, while revenue for the quarter reached $2.50m , missing expectations by -1.92%.
RXRX Stock Performance
Access detailed RXRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
